Dr. Weiwei Huang 黄伟炜
Chief Physician
Department of Medical Oncology for Breast Cancer, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, endocrine therapy, and biological therapies (including molecular targeted therapy and immunotherapy) for breast cancer, as well as comprehensive treatment.
Dr. Huang holds a Master’s in Oncology and graduated from Fujian Medical University in 1997. The doctor has led or participated in over 10 provincial and departmental research projects, receiving the Third Prize of Fujian Provincial Science and Technology Progress. Dr. Huang contributed to several monographs, published over 10 papers as first or corresponding author, including three SCI articles, and participated in more than ten international and national new drug clinical trials.
Professional roles
- Member, Breast Disease Training Expert Committee, Chinese Medical Doctor Association
- Member, Breast Disease Professional Committee, China Medicine Education Association
- Member, Medical Oncology Professional Committee, Fujian Anti-Cancer Association
Name order: in Chinese the family name comes first (Huang Weiwei). Papers usually list the name as Weiwei Huang or Huang W.
Selected publications
25 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Res Treat, 2026 (senior author): Apatinib Mesylate in the Treatment of Advanced Triple-Negative Breast Cancer. PubMed 41701668
- Front Pharmacol, 2025 (first author): Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China. PubMed 41560743
- Oncol Ther, 2025 (senior author): Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer. PubMed 40952644
- Methods Mol Biol, 2025 (first author): CRISPR-Mediated Viral Gene Knock-In for Studying Viral-Host Interactions. PubMed 40515905
- BMC Cancer, 2024 (first author): Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer. PubMed 38528446
- Front Cell Dev Biol, 2024 (first author): Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study. PubMed 38481526
- BMC Cancer, 2024 (first author): A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer. PubMed 38182995
- Onco Targets Ther, 2020 (first author): Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer. PubMed 32943874
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion